Terminally ill patients do not have a constitutional right to experimental drugs not approved by regulators, a U.S. appeals court ruled on Tuesday...
“The FDA’s policy of limiting access to investigational drugs is rationally related to the legitimate state interest of protecting patients, including the terminally ill, from potentially unsafe drugs with unknown therapeutic effects,” Judge Thomas Griffith wrote in Tuesday’s majority opinion.
